MCID: RCT021
MIFTS: 58

Rectum Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Rectum Cancer

MalaCards integrated aliases for Rectum Cancer:

Name: Rectum Cancer 12 15 17
Rectal Cancer 12 56 15
Malignant Neoplasm of Rectum 12
Malignant Tumor of Rectum 12
Carcinoma of the Rectum 12
Malignant Rectal Tumor 12
Malignant Rectum Tumor 12
Carcinoma of Rectum 12
Cancer of Rectum 12
Rectal Carcinoma 56
Rectal Neoplasms 45
Cancer, Rectal 41

Classifications:



External Ids:

Disease Ontology 12 DOID:1993
ICD9CM 36 154.1
MeSH 45 D012004
NCIt 51 C7418 C9382
SNOMED-CT 69 93984006
ICD10 34 C20

Summaries for Rectum Cancer

Disease Ontology : 12 A colorectal cancer that is located in the rectum.

MalaCards based summary : Rectum Cancer, also known as rectal cancer, is related to lynch syndrome and rectum adenocarcinoma. An important gene associated with Rectum Cancer is TYMS (Thymidylate Synthetase), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Avastin and Campostar have been mentioned in the context of this disorder. Affiliated tissues include colon, lymph node and breast, and related phenotypes are no effect and Increased viability with MLN4924 (a NAE inhibitor)

Related Diseases for Rectum Cancer

Diseases in the Rectum Cancer family:

Rectum Carcinoma in Situ

Diseases related to Rectum Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 316)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 32.2 APC KRAS MLH1 MSH2 MUTYH
2 rectum adenocarcinoma 31.4 CAGE1 CEACAM5 KRT20 RAB11B RAB1A
3 familial adenomatous polyposis 30.5 APC KRAS MLH1 MSH2 MUTYH
4 colorectal cancer 30.3 APC CDKN1A CEACAM3 CEACAM5 CEACAM7 DPYD
5 anal fistula 30.3 MLH1 MSH2
6 attenuated familial adenomatous polyposis 29.9 APC MSH2 MUTYH
7 adenoma 29.8 APC KRAS MLH1 MSH2 MUTYH
8 cholangiocarcinoma 29.5 CEACAM3 CEACAM5 KRAS KRT20 MMP7
9 esophageal cancer 29.4 CDKN1A CEACAM5 DPYD KRAS MMP7 TYMP
10 lung cancer 29.3 CDKN1A CEACAM5 KRAS KRT20 MLH1 MMP7
11 endometrial cancer 29.3 CDKN1A KRAS MLH1 MMP7 MSH2 MUTYH
12 gastric cancer 28.8 APC CDKN1A CEACAM5 DPYD KRAS KRT20
13 rectal cancer, childhood 12.2
14 rectum sarcoma 11.2
15 rectum squamous cell carcinoma 11.2
16 rectal cloacogenic carcinoma 11.2
17 rectum sarcomatoid carcinoma 11.2
18 squamous cell carcinoma 10.6
19 appendix carcinoid tumor 10.4 MLH1 MSH2
20 colorectal cancer, hereditary nonpolyposis, type 7 10.4 MLH1 MSH2
21 adenosquamous colon carcinoma 10.4 MLH1 MSH2
22 sigmoid neoplasm 10.4 CEACAM5 KRAS
23 sebaceous adenoma 10.4 MLH1 MSH2
24 lower lip cancer 10.4 MLH1 MSH2
25 lymphomatous meningitis 10.4 CEACAM5 TYMP
26 apocrine adenoma 10.4 CEACAM5 KRAS
27 colorectal cancer 5 10.4 DPYD MLH1
28 urachal adenocarcinoma 10.4 CEACAM5 KRAS
29 lip cancer 10.4 CDKN1A MSH2
30 actinic cheilitis 10.4 CDKN1A MSH2
31 gastrointestinal carcinoma 10.4 DPYD KRT20 TYMS
32 pancreatic cystadenocarcinoma 10.4 CEACAM5 KRAS
33 periampullary adenoma 10.3 APC KRAS
34 fibroepithelial basal cell carcinoma 10.3 CEACAM5 KRT20
35 skin benign neoplasm 10.3 KRT20 MLH1 MSH2
36 papilloma 10.3 CDKN1A KRT20 TYMS
37 mucinous adenocarcinoma 10.3 KRAS KRT20 MLH1
38 muir-torre syndrome 10.3 MLH1 MSH2 MUTYH
39 atypical follicular adenoma 10.3 CDKN1A CEACAM5
40 biliary papillomatosis 10.3 CEACAM5 KRAS KRT20
41 keratoacanthoma 10.3 CDKN1A MLH1 MSH2
42 vulval paget's disease 10.3 CEACAM5 KRT20
43 patulous eustachian tube 10.3
44 autosomal genetic disease 10.3 MLH1 MSH2 MUTYH
45 bile duct cystadenocarcinoma 10.3 CEACAM5 KRT20
46 polyposis syndrome, hereditary mixed, 1 10.3 APC MLH1 MUTYH
47 mismatch repair cancer syndrome 10.3 APC MLH1 MSH2
48 goblet cell carcinoid 10.3 CEACAM7 KRT20
49 hyperplastic polyposis syndrome 10.3 APC KRAS MUTYH
50 mutyh-associated polyposis 10.3 APC KRAS MUTYH

Graphical network of the top 20 diseases related to Rectum Cancer:



Diseases related to Rectum Cancer

Symptoms & Phenotypes for Rectum Cancer

GenomeRNAi Phenotypes related to Rectum Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 APC CAGE1 CDKN1A CEACAM3 CEACAM5 CEACAM7
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 CDKN1A CEACAM3 MLH1 MSH2 MUTYH TYMS

MGI Mouse Phenotypes related to Rectum Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 APC CDKN1A KRAS MLH1 MMP7 MSH2

Drugs & Therapeutics for Rectum Cancer

FDA approved drugs:

(show all 11)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Avastin 19 50 BEVACIZUMAB Genentech July 2009
2
Campostar 19 50 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn June 1996
3
CEA-Scan 19 Immunomedics April 1996
4
Cyramza 19 50 RAMUCIRUMAB Eli Lilly April 2014
5
Eloxatin 19 50 OXALIPLATIN Sanofi-aventis August 2002
6
Erbitux 19 50 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
7
Fusilev 19 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
8
Stivarga 19 50 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
9
Vectibix 19 50 PANITUMUMAB Amgen September 2006
10
Xeloda 19 50 CAPECITABINE Roche April 1998/ May 2001
11
Zaltrap 19 50 ZIV-AFLIBERCEPT Sanofi-aventis August 2012

Drugs for Rectum Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 556)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
3
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
4
Bupivacaine Approved, Investigational Phase 4,Not Applicable 2180-92-9, 38396-39-3 2474
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
7
Acetaminophen Approved Phase 4 103-90-2 1983
8
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
9
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 93-14-1 3516
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Orphenadrine Approved Phase 4 83-98-7 4601
12
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
13
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
14
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
15
Methadone Approved Phase 4 76-99-3 4095
16
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 6857599 5310940 9887054 43805
17
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
18
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
19
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
20
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
21
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
22
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
23
Udenafil Approved, Investigational Phase 4,Phase 2 268203-93-6 6918523
24
Sodium Citrate Approved, Investigational Phase 4 68-04-2
25
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
26
Darbepoetin alfa Approved, Investigational Phase 4 11096-26-7, 209810-58-2
27
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
28
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-70-2 271
29
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
30 Cola Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
32 Ketorolac Tromethamine Phase 4
33 Parasympatholytics Phase 4,Phase 3
34 Antimanic Agents Phase 4,Phase 1,Phase 2
35 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
37 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
38 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Excitatory Amino Acid Antagonists Phase 4,Phase 2
40 Neuromuscular Agents Phase 4,Phase 2
41 Anti-Arrhythmia Agents Phase 4,Phase 3
42 Antiparkinson Agents Phase 4,Phase 3,Phase 2
43 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 Cholinergic Antagonists Phase 4,Phase 3
45 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
47 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
48 Sodium Channel Blockers Phase 4
49 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Antipyretics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1517)
# Name Status NCT ID Phase Drugs
1 Study of NOTES-TME Versus L-LAR in Rectal Cancer Unknown status NCT02550769 Phase 4
2 Trial to Reduce Wound Infection With Contralateral Drainage in Loop Ileostomy Closure Unknown status NCT02574702 Phase 4
3 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
4 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
5 Prospective Randomized Study of SILS Versus CLS for Rectal Cancer Completed NCT01579721 Phase 4
6 The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer Completed NCT01421940 Phase 4 Placebo drug;Udenafil
7 Early Intervention for Erectile Dysfunction After Laparoscopic Resection for Rectal Cancer Completed NCT01912586 Phase 4
8 The Effect of Dexmedetomidine on Postoperative Analgesia Completed NCT01373021 Phase 4 Fentanyl;Dexmedetomidine
9 The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery Completed NCT00122720 Phase 4 Darbepoetin Alfa
10 Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer Completed NCT00559676 Phase 4 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
11 Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia Recruiting NCT01975064 Phase 4 Propofol;Sevoflurane
12 Complete Mesocolon Excision vs Locoregional Lymphadenectomy in Sigmoid Colon Cancer (CMELL) Not yet recruiting NCT03083951 Phase 4
13 Radial Reload Laparoscopic LAR Case Series Terminated NCT01706822 Phase 4
14 Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma Terminated NCT00216424 Phase 4 Capecitabine (Xeloda)
15 Transanual Tube Placement in Low Anterior Resection (LAR) for Rectal Cancer Unknown status NCT02905968 Phase 2, Phase 3
16 Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer Unknown status NCT01308190 Phase 3 Capecitabine (Xeloda)
17 Preoperative Radiotherapy and Local Excision in Rectal Cancer Unknown status NCT00738790 Phase 3
18 The Randomised Study of Preoperative Radiotherapy With Consolidating Chemotherapy for Unresectable Rectal Cancer Unknown status NCT00833131 Phase 3
19 Simultaneous Integrated Boost Preoperative Radiotherapy for Rectum Cancer Unknown status NCT01224392 Phase 3
20 A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT) Unknown status NCT00601549 Phase 3
21 Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer Unknown status NCT02964468 Phase 3
22 Randomized Trial on Robotic Assisted Resection for Rectal Cancer Unknown status NCT01130233 Phase 3
23 Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer Unknown status NCT00597311 Phase 3
24 A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Unknown status NCT01064999 Phase 2, Phase 3 Oxaliplatin;Capecitabine
25 Randomized Prospective Trial for Laparoscopic vs Open Resection for Rectal Cancer Unknown status NCT00470951 Phase 3
26 Preoperative Hyperfractionated Radiotherapy or Radiochemotherapy in Locally Advanced Rectal Cancer. Unknown status NCT01814969 Phase 3
27 COLOR II: Laparoscopic Versus Open Rectal Cancer Removal Unknown status NCT00297791 Phase 3
28 Resource-Sparing Curative Treatment for Rectal Cancer Unknown status NCT01459328 Phase 3
29 A Trial to Assess Robot-assisted Surgery and Laparoscopy-assisted Surgery in Patients With Mid or Low Rectal Cancer Unknown status NCT01423214 Phase 3
30 Comparison of Two Types of Surgery in Treating Patients With Rectal Cancer Unknown status NCT00007930 Phase 3
31 Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer Unknown status NCT00154752 Phase 3
32 Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer Unknown status NCT00227747 Phase 3 capecitabine;oxaliplatin
33 Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer Unknown status NCT00058474 Phase 3 capecitabine;fluorouracil;oxaliplatin
34 Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer Unknown status NCT02770911 Phase 3
35 Mesh Reinforcement During Temporary Stoma Closure After Sphincter-Saving Rectal Cancer Surgery Unknown status NCT02576184 Phase 3
36 Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study Unknown status NCT01653301 Phase 3 XELAC RT;XELOX RT
37 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
38 5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer Unknown status NCT00189657 Phase 3
39 Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Anterior Resection Unknown status NCT01861678 Phase 3
40 VSL#3 Versus Placebo in Increasing the Pathological Major Response Rate in Patients With Rectal Cancer Unknown status NCT01579591 Phase 3
41 A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment. Unknown status NCT01941979 Phase 3 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
42 β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence Unknown status NCT00888797 Phase 3 Propranolol and Etodolac
43 J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma Unknown status NCT00070005 Phase 3
44 Monitoring by Microdialysis of Postoperative Complications After Proctectomy Unknown status NCT01999634 Phase 3
45 Increasing Colorectal Cancer Screening in African Americans Unknown status NCT00893295 Phase 3
46 Personalized Screening Plans to Increase Colorectal Cancer Screening in Healthy Participants Unknown status NCT00617071 Phase 3
47 Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer. Unknown status NCT00337389 Phase 3 5- Fluorouracil (5-FU);bevacizumab (Avastin);Leucovorin;CoFactor (ANX-510)
48 Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Unknown status NCT00797485 Phase 3 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium
49 Electroacupuncture Versus Fast-track Perioperative Program for Laparoscopic Colorectal Surgery Unknown status NCT02059603 Phase 3
50 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium Unknown status NCT02928692 Phase 3 Minocycline;Placebo

Search NIH Clinical Center for Rectum Cancer

Cochrane evidence based reviews: rectal neoplasms

Genetic Tests for Rectum Cancer

Anatomical Context for Rectum Cancer

MalaCards organs/tissues related to Rectum Cancer:

42
Colon, Lymph Node, Breast, Testes, Endothelial, Prostate, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Rectum Cancer:

20
The Rectum

Publications for Rectum Cancer

Articles related to Rectum Cancer:

(show top 50) (show all 2920)
# Title Authors Year
1
Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. ( 30838175 )
2019
2
Feasibility of restorative proctocolectomy in patients with ulcerative colitis-associated lower rectal cancer: A retrospective study. ( 29454571 )
2019
3
Late-Onset Lung Metastasis in Rectum Cancer Can Be Confused with Primary Lung Cancer; a Case Report and Literature Review. ( 30613927 )
2019
4
Thrombospondin type-1 domain-containing 7A-associated membranous nephropathy after resection of rectal cancer: a case report. ( 30727973 )
2019
5
Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment. ( 30871581 )
2019
6
Synchronous primary cancers: Renal cell carcinoma and rectal cancer. ( 30880786 )
2019
7
Visceral obesity and short-term outcomes after laparoscopic rectal cancer resection. ( 30887182 )
2019
8
Obesity as an independent predictive factor for pathologic complete response after neoadjuvant chemoradiation in rectal cancer. ( 30838183 )
2019
9
The obesity paradox in beyond total mesorectal excision surgery for locally advanced and recurrent rectal cancer. ( 30790208 )
2019
10
Oncologic evaluation of obesity as a factor in patients with rectal cancer undergoing laparoscopic surgery: a propensity-matched analysis using body mass index. ( 30746356 )
2019
11
The effect of increased body mass index values on surgical outcomes after radical resection for low rectal cancer. ( 30778736 )
2019
12
The Association of Preoperative Anemia and the Postoperative Course and Oncological Outcome in Patients Undergoing Rectal Cancer Surgery: A Multicenter Snapshot Study. ( 30870224 )
2019
13
Impact of nominal photon energies on normal tissue sparing in knowledge-based radiotherapy treatment planning for rectal cancer patients. ( 30845263 )
2019
14
Magnetic-Resonance-Imaging Texture Analysis Predicts Early Progression in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiation. ( 30847005 )
2019
15
ASO Author Reflections: Similar Short- and Long-Term Outcomes in Variable Use and Timing of Restaging MRI and Surgery After Preoperative Chemoradiotherapy for Rectal Cancer. ( 30847749 )
2019
16
Accuracy of endoscopic ultrasound in rectal cancer and its use in transanal endoscopic microsurgery. ( 30849259 )
2019
17
Minimally Invasive Surgery for Locally Advanced Rectal Cancer. ( 30851830 )
2019
18
Nonoperative management after neoadjuvant therapy for rectal cancer: A single institution experience over 5 years. ( 30851884 )
2019
19
Association between diabetes and oncological outcomes in patients undergoing neoadjuvant chemo-radiotherapy for rectal cancer. ( 30851913 )
2019
20
Prediction of efficacy of neoadjuvant chemoradiotherapy for rectal cancer: the value of texture analysis of magnetic resonance images. ( 30852633 )
2019
21
Hospital and surgeon variation in positive circumferential resection margin among rectal cancer patients. ( 30853095 )
2019
22
Palliative beam radiotherapy offered real-world survival benefit to metastatic rectal cancer: A large US population-based and propensity score-matched study. ( 30854131 )
2019
23
Survival Benefit of Preoperative Versus Postoperative Radiotherapy in Metastatic Rectal Cancer Treated With Definitive Surgical Resection of Primary Tumor: A Population Based, Propensity Score-Matched Study. ( 30854140 )
2019
24
A Non-Operative Approach to Rectal Cancer after Chemo-Radiotherapy: Case Series and Review. ( 30854164 )
2019
25
Pulmonary metastasis in newly diagnosed colon-rectal cancer: a population-based nomogram study. ( 30854572 )
2019
26
Computerized Tomography Criteria as a Tool for Simplifying the Assessment of Locally Advanced Rectal Cancer. ( 30854604 )
2019
27
Systematic review and meta-analysis on outcomes of salvage therapy in patients with tumour recurrence during 'watch and wait' in rectal cancer. ( 30855163 )
2019
28
Predictive Factors for Bowel Dysfunction After Sphincter-Preserving Surgery for Rectal Cancer: A Single-Center Cross-sectional Study. ( 30855308 )
2019
29
Robotic posterior pelvic exenteration for locally advanced rectal cancer: Video vignette. ( 30856286 )
2019
30
Phase I/II trial of Nano-camptothecin CRLX101 with Capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal Cancer. ( 30858085 )
2019
31
Performance of the eclipse monitor unit objective tool utilizing volumetric modulated arc therapy for rectal cancer. ( 30858766 )
2019
32
Value of High-Resolution DWI in Combination With Texture Analysis for the Evaluation of Tumor Response After Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer. ( 30860889 )
2019
33
Impact of enhanced recovery on oncological outcomes following minimally invasive surgery for rectal cancer. ( 30861099 )
2019
34
Watch and Wait in Rectal Cancer: Who's In and Who's Out? ( 30861365 )
2019
35
Redefining Rectal Cancer Priorities Through a Watch-and-Wait Paradigm: Balancing Cancer Cure and Quality of Life. ( 30861366 )
2019
36
Nonsurgical Management of Rectal Cancer. ( 30861368 )
2019
37
Anastomotic leakage following laparoscopic resection of low and mid rectal cancer. ( 30862768 )
2019
38
Laparoscopic modified double stapling technique with transanal resection for low anterior resection of rectal cancer. ( 30862771 )
2019
39
Concomitant dose escalation with image-guided Tomotherapy in locally advanced mid-low rectal cancer: a single-center study. ( 30863168 )
2019
40
Correction: The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy. ( 30863500 )
2019
41
Delta-radiomics signature predicts treatment outcomes after preoperative chemoradiotherapy and surgery in rectal cancer. ( 30866965 )
2019
42
Local environment in biopsy better predict the pathological response to neoadjuvant chemoradiotherapy in rectal cancer. ( 30867256 )
2019
43
The Application of Extraperitoneal Ostomy Combined with Pelvic Peritoneal Reconstruction in Laparoscopic Abdominoperineal Resection for Rectal Cancer. ( 30867662 )
2019
44
Open versus minimally invasive surgery for rectal cancer: a single-center cohort study on 237 consecutive patients. ( 30868546 )
2019
45
Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. ( 30868576 )
2019
46
Organ Preservation Among Patients With Clinically Node-Positive Rectal Cancer: Is It Really More Dangerous? ( 30870223 )
2019
47
Quality of Life After Curative Resection for Rectal Cancer in Patients Treated With Adjuvant Chemotherapy Compared With Observation: Results of the Randomized Phase III SCRIPT Trial. ( 30870225 )
2019
48
Radial incision and cutting method using a transanal approach for treatment of anastomotic strictures following rectal cancer surgery: a case report. ( 30871591 )
2019
49
Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy. ( 30874889 )
2019
50
Has adherence to treatment guidelines for mid/low rectal cancer affected the management of patients? A monocentric study of 604 consecutive patients. ( 30876923 )
2019

Variations for Rectum Cancer

Copy number variations for Rectum Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 139647 2 185171337 185512459 Copy number ZNF804A Rectal cancer
2 166960 3 1109627 1420278 Copy number CNTN6 Rectal cancer
3 225401 7 45400000 54000000 Copy number EGFR Rectal cancer

Expression for Rectum Cancer

Search GEO for disease gene expression data for Rectum Cancer.

Pathways for Rectum Cancer

GO Terms for Rectum Cancer

Cellular components related to Rectum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 8.62 MLH1 MSH2

Biological processes related to Rectum Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.85 APC CDKN1A MLH1 MSH2 MUTYH
2 response to glucocorticoid GO:0051384 9.58 CDKN1A KRAS TYMS
3 somatic hypermutation of immunoglobulin genes GO:0016446 9.51 MLH1 MSH2
4 isotype switching GO:0045190 9.49 MLH1 MSH2
5 pyrimidine nucleoside catabolic process GO:0046135 9.48 DPYD TYMP
6 positive regulation of isotype switching to IgG isotypes GO:0048304 9.43 MLH1 MSH2
7 positive regulation of isotype switching to IgA isotypes GO:0048298 9.37 MLH1 MSH2
8 intestinal epithelial cell maturation GO:0060574 9.32 CDKN1A TYMS
9 pyrimidine nucleobase metabolic process GO:0006206 9.26 TYMP TYMS
10 somatic recombination of immunoglobulin gene segments GO:0016447 9.16 MLH1 MSH2
11 mismatch repair GO:0006298 9.13 MLH1 MSH2 MUTYH
12 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 8.62 MLH1 MSH2

Molecular functions related to Rectum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatched DNA binding GO:0030983 9.32 MLH1 MSH2
2 MutLalpha complex binding GO:0032405 9.26 MSH2 MUTYH
3 MutSalpha complex binding GO:0032407 9.16 MLH1 MUTYH
4 oxidized purine DNA binding GO:0032357 8.96 MSH2 MUTYH
5 guanine/thymine mispair binding GO:0032137 8.62 MLH1 MSH2

Sources for Rectum Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....